Recent News

• 04.15.2025 - Mural Oncology Announces Plans to Explore Strategic Alternatives
• 04.15.2025 - Mural Oncology Announces Plans to Explore Strategic Alternatives
• 04.15.2025 - Mural Oncology Announces Plans to Explore Strategic Alternatives
• 04.15.2025 - Mural Oncology Announces Plans to Explore Strategic Alternatives
• 03.25.2025 - Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
• 03.25.2025 - Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
• 03.25.2025 - Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
• 03.25.2025 - Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
• 03.11.2025 - Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
• 03.11.2025 - Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones

Recent Filings

• 03.25.2025 - 8-K Current report
• 03.11.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.11.2025 - 8-K Current report
• 03.11.2025 - EX-99.1 EX-99.1
• 03.11.2025 - 8-K Current report
• 03.11.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.11.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.05.2025 - 144 Report of proposed sale of securities